These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12636887)

  • 21. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?
    Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E
    Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moving forward with capecitabine: a glimpse of the future.
    Biganzoli L; Martin M; Twelves C
    Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel in anthracycline-resistant metastatic breast cancer.
    Hui YF; Ignoffo RJ
    Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of a patient with a triple negative breast cancer and complete response of lung, mediastinal and skeletal metastases after treatment with paclitaxel and bevacizumab].
    Bravencová Z
    Klin Onkol; 2010; 23(5):358-60. PubMed ID: 21061684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.
    Dagnaes-Hansen F; Rasmussen LM; Tilton R; Denner L; Flyvbjerg A
    Anticancer Res; 2003; 23(2B):1625-30. PubMed ID: 12820432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer.
    O'Shaughnessy JA; Brufsky AM
    Clin Breast Cancer; 2008 Aug; 8(4):370-3. PubMed ID: 18757267
    [No Abstract]   [Full Text] [Related]  

  • 27. Bevacizumab: new indication. Metastatic breast cancer: many adverse effects.
    Prescrire Int; 2008 Dec; 17(98):236. PubMed ID: 19422148
    [No Abstract]   [Full Text] [Related]  

  • 28. Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer.
    Wilson TJ; Heth JA
    J Clin Neurosci; 2012 Mar; 19(3):468-9. PubMed ID: 22245272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.
    Hamilton A; Larsimont D; Paridaens R; Drijkoningen M; van de Vijver M; Bruning P; Hanby A; Houston S; Treilleux I; Guastalla JP; Van Vreckem A; Sylvester R; Piccart M
    Clin Breast Cancer; 2000 Oct; 1(3):233-40; discussion 241-2. PubMed ID: 11899648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The molecular perspective: VEGF and angiogenesis.
    Goodsell DS
    Stem Cells; 2003; 21(1):118-9. PubMed ID: 12529559
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of antiangiogenetic agents in the treatment of breast cancer.
    Bareschino MA; Schettino C; Colantuoni G; Rossi E; Rossi A; Maione P; Ciardiello F; Gridelli C
    Curr Med Chem; 2011; 18(33):5022-32. PubMed ID: 22050750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F; Borgonovo K; Barni S
    Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.
    Murphy CG; Khasraw M; Seidman AD
    Breast Cancer Res Treat; 2010 Jul; 122(1):177-9. PubMed ID: 20458530
    [No Abstract]   [Full Text] [Related]  

  • 35. [Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice].
    Campone M; Fumoleau P
    Bull Cancer; 2002 Mar; 89(3):275-82. PubMed ID: 11940467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
    Farhat MH; El-Saghir NS; Shamseddine AI
    Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Taxanes in the treatment of breast cancer: a prodigy comes of age.
    Miller KD; Sledge GW
    Cancer Invest; 1999; 17(2):121-36. PubMed ID: 10071597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
    Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
    Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab and breast cancer: the E2100 outlier.
    Fojo T; Wilkerson J
    Lancet Oncol; 2010 Dec; 11(12):1117-9. PubMed ID: 21126685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.